Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China · Delayed Price · Currency is CNY 15.66
+0.52 (3.43%)
Apr 29, 2026, 3:00 PM CST
Cisen Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 421.25 | 508.91 | 521.34 | 349.96 | 334.15 |
Depreciation & Amortization | 197.38 | 222.72 | 233.89 | 230.25 | 219.49 |
Other Amortization | 4.38 | 2.09 | 1.96 | 0.98 | 3.14 |
Loss (Gain) From Sale of Assets | 0.71 | 0.14 | -0.59 | -0.97 | -0.27 |
Asset Writedown & Restructuring Costs | 10.85 | -3.53 | 74.27 | 13.06 | 21.34 |
Loss (Gain) From Sale of Investments | -163.15 | -72.83 | -33.74 | -15.56 | -66.42 |
Provision & Write-off of Bad Debts | 59.13 | 56.03 | 2.34 | 16.46 | -5.92 |
Other Operating Activities | 6.36 | 12.44 | 10.84 | 6.83 | -1.68 |
Change in Accounts Receivable | -102.24 | -20.82 | -336.44 | -542.34 | -113.29 |
Change in Inventory | 178.69 | -115.04 | -144.31 | 18.1 | -14.81 |
Change in Accounts Payable | -144 | 4.69 | 118.51 | 197.67 | -113.8 |
Change in Other Net Operating Assets | -9.34 | -25.94 | -4.92 | -18.73 | -9.26 |
Operating Cash Flow | 466.37 | 570.85 | 451.24 | 258.35 | 233.6 |
Operating Cash Flow Growth | -18.30% | 26.51% | 74.67% | 10.59% | -45.80% |
Capital Expenditures | -64.76 | -101.81 | -17.71 | -35.19 | -51.02 |
Sale of Property, Plant & Equipment | 3.36 | 0.49 | 0.76 | 0.01 | 0.49 |
Cash Acquisitions | - | - | 0.42 | - | - |
Investment in Securities | -265.53 | 16 | -408.36 | -274.13 | 289.99 |
Other Investing Activities | 153.12 | 63.57 | 46.77 | 36.23 | 88.02 |
Investing Cash Flow | -173.82 | -21.75 | -378.13 | -273.08 | 327.48 |
Short-Term Debt Issued | 12.08 | 26.87 | 30.98 | - | - |
Long-Term Debt Issued | 15.34 | 53.33 | 54 | 250 | 138 |
Total Debt Issued | 27.43 | 80.19 | 84.98 | 250 | 138 |
Long-Term Debt Repaid | -73.33 | -137.25 | -59.05 | -232.43 | -340.24 |
Total Debt Repaid | -73.33 | -137.25 | -59.05 | -232.43 | -340.24 |
Net Debt Issued (Repaid) | -45.9 | -57.06 | 25.93 | 17.57 | -202.24 |
Common Dividends Paid | -182.92 | -304.56 | -156.13 | -139.54 | -120.73 |
Other Financing Activities | -3.14 | -3.02 | -3.6 | 230.16 | 4.54 |
Financing Cash Flow | -231.96 | -364.63 | -133.8 | 108.19 | -318.43 |
Foreign Exchange Rate Adjustments | -0.79 | 0.36 | 0.65 | 0.65 | -0.22 |
Net Cash Flow | 59.8 | 184.83 | -60.04 | 94.11 | 242.43 |
Free Cash Flow | 401.61 | 469.04 | 433.53 | 223.15 | 182.58 |
Free Cash Flow Growth | -14.38% | 8.19% | 94.27% | 22.22% | -20.18% |
Free Cash Flow Margin | 11.66% | 11.78% | 9.71% | 5.49% | 4.83% |
Free Cash Flow Per Share | 0.89 | 1.03 | 0.96 | 0.49 | 0.40 |
Cash Interest Paid | 0.9 | 1.91 | 0.6 | 0.44 | 0.38 |
Cash Income Tax Paid | 334.19 | 389.98 | 433.03 | 357.12 | 390.99 |
Levered Free Cash Flow | 499.95 | 483.53 | 443.54 | 283.19 | 137.89 |
Unlevered Free Cash Flow | 500.79 | 487.87 | 447.66 | 285.87 | 141.7 |
Change in Working Capital | -70.55 | -155.1 | -359.05 | -342.66 | -270.23 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.